Radiolabeled Growth Factors

CAS: 110-61-2 EC No: 203-783-9 MDL No: MFCD00001949 RTECS: WN3850000 UN No: UN3439 Haz Class: 6.1 Packing Group: III Crystalline Molecular Formula: C₄H₄N₂ MW: 80.

CAS: 110-61-2 EC No: 203-783-9 MDL No: MFCD00001949 RTECS: WN3850000 UN No: UN3439 Haz Class: 6.1 Packing Group: III Crystalline Molecular Formula: C₄H₄N₂ MW: 80.

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth

increasing ion transport by mutant-CFTR.